Is the price fair?
What SRPT's price assumes
Sarepta Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 1.21× revenue.
1.21
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 6.2%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- +2.8%
Growth the price implies · The price pays for +2.8% free cash flow growth a year for a decade; revenue has grown +31% a year over the last three.
- Price / book
- 1.76
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 1.76
- EV / EBIToperating margin −1.9%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 1.39
- Free cash flow, trailing twelve months
- $115M
- Market capitalisation
- $1.85B
- 3-year revenue growth
- +31%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.